Real-World Data on Pathological Response and Survival Outcomes After Neoadjuvant Chemotherapy in HER2-Low Breast Cancer Patients
Clinical Breast Cancer · 2024
DOI: 10.1016/j.clbc.2024.04.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Breast Cancer, 2024. Verfasst von Dandan Guan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Suzhou Medical College of Soochow University, Soochow, China; General Surgery, Cancer Center, Department of Breast Surgery, Zhejiang Provincial Peopl…. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Neoadjuvant Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Zhejiang Traditional Chinese Medicine Administration, National Natural Science Foundation of China, Department of Education of Zhejiang Province.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Suzhou Medical College of Soochow University, Soochow, China; General Surgery, Cancer Center, Department of Breast Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College,…
- Department of Urinary Surgery, Haining branch of Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Jiaxing, Zhejiang, China.
- General Surgery, Cancer Center, Department of Breast Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China; Key Laboratory for diagnosis and t…
- Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Förderung
- Zhejiang Traditional Chinese Medicine Administration
- National Natural Science Foundation of China
- Department of Education of Zhejiang Province
Zitieren
APA
Guan, D., Shi, Q., Zheng, Y., Zheng, C., & Meng, X. (2024). Real-World Data on Pathological Response and Survival Outcomes After Neoadjuvant Chemotherapy in HER2-Low Breast Cancer Patients. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2024.04.006
Vancouver
Guan D, Shi Q, Zheng Y, Zheng C, Meng X. Real-World Data on Pathological Response and Survival Outcomes After Neoadjuvant Chemotherapy in HER2-Low Breast Cancer Patients. Clinical Breast Cancer. 2024. doi:10.1016/j.clbc.2024.04.006
BibTeX
@article{Guan2024,
author = {Guan, Dandan and Shi, Qingyang and Zheng, Yajuan and Zheng, Chaopeng and Meng, Xuli},
title = {Real-World Data on Pathological Response and Survival Outcomes After Neoadjuvant Chemotherapy in HER2-Low Breast Cancer Patients},
journal = {Clinical Breast Cancer},
year = {2024},
doi = {10.1016/j.clbc.2024.04.006}
}
EUVIMED